All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu
Go back to All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu| (NASDAQ: JAGX) | Delayed: 34.46 +31.79 (1,190.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.67 | 52 Week High | $4.60 | |||
| Open | $2.83 | 52 Week Low | $0.81 | |||
| Day High | $41.53 | P/E | N/A | |||
| Day Low | $2.75 | EPS | $0.00 | |||
| Volume | 27,891,438 | |||||
